While some studies have focused on inhibiting FTO in certain cancers where it functions as an oncogene, such as in acute myeloid leukemia (Huang et al., 2019; Niu et al., 2019), our data clearly position FTO as a protective factor in the context of glioma, where its loss contributes to disease progression. This evidence concerns the gene FTO and central nervous system cancer.